Comparative Pharmacology
Head-to-head clinical analysis: ACAMPROSATE CALCIUM versus ANTABUSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACAMPROSATE CALCIUM versus ANTABUSE.
ACAMPROSATE CALCIUM vs ANTABUSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Modulates glutamatergic neurotransmission by antagonizing NMDA receptors and potentiating GABAergic activity, restoring the balance between neuronal excitation and inhibition in alcohol dependence.
Irreversibly inhibits aldehyde dehydrogenase (ALDH), causing accumulation of acetaldehyde after alcohol ingestion, leading to aversive reaction.
666 mg (two 333 mg tablets) orally three times daily, total daily dose 1998 mg. Initiate as soon as possible after abstinence is achieved; maintain for 12 months.
250 mg orally once daily, initiated after 12 hours of no alcohol intake; maintenance dose may be reduced to 125 mg daily based on tolerance.
None Documented
None Documented
Terminal elimination half-life: 20–30 hours; steady-state reached after 5–7 days.
10.8 ± 3.5 hours (range 6-16 hours) for disulfiram; metabolites (e.g., 2-mercapto-2-methyl-4-butyl-γ-thiobutyrolactone) have prolonged half-lives up to 120-200 hours, contributing to sustained sensitivity to ethanol.
Renal excretion as unchanged drug: 90%; fecal: <1%; minor biliary elimination.
Primarily renal: 80-90% as metabolites (mainly diethyldithiocarbamate and its glucuronide, plus sulfate esters) within 24 hours; <20% fecal (unabsorbed disulfiram and biliary metabolites).
Category C
Category C
Alcohol Deterrent
Alcohol Deterrent